Save the date for this informative and wide-ranging webinar that will be presented by:
Associate Professor Henrik Falhammar
Senior Consultant Endocrinologist & General Physician
Director of Research and Education
Karolinska University Hospital, Sweden
and
Department of Molecular Medicine and Surgery
Karolinska Institute, Sweden
Register using the link below. If you cannot attend register and you will be sent the recording.
Endo-ERN has endorsed an upcoming course by Endo-ERN HCP, Leiden University Medical Center (LUMC).
The 4th CAre for PITuitary Adenoma Leiden (CAPITAL) Course will be held March 21-22, 2024 at LUMC. This event is attended by experienced neurosurgeons, endocrinologists, and other professionals from all over the world. During these two days the focus is on improving outcomes for patients with pituitary adenoma.
Course directors Nienke Biermasz (ENT), Marco Verstegen (NS), Wouter van Furth (NS) & Leontine Bakker (ENT) have composed an interesting program with fantastic faculty.
The programme highlights include:
Obtaining quality and remission in acromegaly The prolactinoma experience Bridging [...]
Calling all experts interested in exploring the psychological, molecular, and administrative aspects of CDH1-related hereditary diffuse type gastric cancer! This workshop will offer invaluable insights into the latest research findings and best practices in patient care. The registration for this upcoming ERN workshops is now open:
CDH1 Related Hereditary Diffuse Type Gastric Cancer: the shift from prophylactic total gastrectomy to optimal endoscopic surveillance
Registration deadline 15 July 2023
Learn more and register using the link below.
Calling all researchers, clinicians, and healthcare specialists interested in cutting-edge advancements! The registration for this upcoming ERN workshops is now open:
Advances in Regenerative Medicine and Tissue Engineering for Rare Musculo-Skeletal Diseases
Discover the latest breakthroughs in regenerative medicine and tissue engineering specifically tailored for rare musculo-skeletal diseases. Join us for this incredible opportunity to learn from renowned experts in the field.
Registration deadline 01 July 2023
Learn more and register using the link below.
Inspiration and innovation were the driving forces behind Dr Dirk Jan Stenvers application to the ERN Exchange Programme.
Dr Stenvers, a clinical endocrinologist at Amsterdam UMC, had his interest piqued by recent publications and congress presentations by the Endocrinology team at University Hospital Basel, Switzerland. Development of copeptin-based diagnostic tests for arginin vasopressin deficiency (previously known as diabetes insipidus) is just one example of innovations that the UHB team are working on. Copeptin based tests are a welcome alternative to the water deprivation test which is a challenging experience for most patients.
Over the course of 4 days, exchange host [...]
This survey aims to collect information on the status quo on ERNs and Clinical Research.
It is developed by ERICA WP4 Clinical Trial Support on the basis of the previous survey delivered in 2018.
The results of the two surveys will be compared to provide a more comprehensive state-of-the-art of ERNs and clinical research.
The survey is addressed both to ERN Coordinators and their ERN HCP members.
Please fill in the survey here: https://ec.europa.eu/eusurvey/runner/ERICAsurvey
The survey will be open until 15th June.
Under Horizon Europe, the European Commission together with member states and associated countries decided to implement the Rare Diseases Partnership which brings a unique vision that aims at leaving no one behind by supporting robust patient need-led research, by utilising and maximising the power of health and research data, by engaging and coordinating regional, national, EU and international alignment in order to accelerate the development of new treatments and diagnostic pathways.
To build its strategy on the voice and input of all stakeholders and as part of the preparatory process of this future Rare Diseases Partnership (foreseen start in 2024) [...]
